Introduction Introduction
Famciclovir orally administered pro-drug of the antiviral agent penciclovir little or no parent compound is recovered in blood or urine licensed in adults for treatment of herpes zoster and herpes simplex infections (125 -750 mg) PK extensively studied in adults -clinical success No population PK analysis has been published Limited information about the PK in paediatrics Two attempts (post filing) were terminated earlyrecruitment issues, probably related to relatively intensive sampling 
Simulations
Reference values obtained for weight and serum creatinine (adults and paediatric age groups) to allow extrapolation of PK model Dose adjusted to achieve the same AUC and Cmax as obtained for a 500mg adult dose 
Sample size calculations Sample size calculations
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Results

Results --modelling modelling
Time ( 
Conclusion Conclusion
A population PK model for adults and paediatrics has been described Adult clearance and total volume of distribution values are comparable to published values from noncompartmental analysis Age and CRCL in addition to weight are needed to explain the IIV on clearance There is a need for dose adjustment in paediatrics and 10mg/kg weight is adequate based on simulation An important area of application of optimal design is paediatric population (limited sampling -ethical and practical constraint) -help to define only the important sampling times Future famciclovir paediatric studies using appropriate dose, limited sampling designs and adequate number of subject have been determined
